Royal Bank of Canada Issues Pessimistic Forecast for Avantor (NYSE:AVTR) Stock Price

Avantor (NYSE:AVTR) had its price objective trimmed by Royal Bank of Canada from $33.00 to $31.00 in a research report released on Monday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other research analysts also recently weighed in on the stock. Stifel Nicolaus reduced their price target on shares of Avantor from $28.00 to $26.00 and set a “buy” rating for the company in a research report on Monday. Robert W. Baird reduced their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating for the company in a research report on Monday, October 28th. Barclays reduced their price target on shares of Avantor from $26.00 to $23.00 and set an “overweight” rating for the company in a research report on Monday. UBS Group reiterated a “neutral” rating and issued a $25.00 price objective (down previously from $29.00) on shares of Avantor in a report on Friday, January 17th. Finally, Wells Fargo & Company cut their price objective on shares of Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Monday. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Avantor presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.15.

Avantor Trading Down 1.8 %

Shares of Avantor stock opened at $18.06 on Monday. Avantor has a fifty-two week low of $18.00 and a fifty-two week high of $28.00. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.06 and a current ratio of 1.54. The firm has a 50-day simple moving average of $21.63 and a two-hundred day simple moving average of $23.39. The company has a market cap of $12.29 billion, a P/E ratio of 39.26, a price-to-earnings-growth ratio of 3.87 and a beta of 1.28.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.27 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.01. Avantor had a net margin of 4.54% and a return on equity of 12.24%. During the same quarter in the prior year, the firm posted $0.22 earnings per share. As a group, equities analysts predict that Avantor will post 0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Avantor

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System boosted its position in Avantor by 0.3% in the 4th quarter. Louisiana State Employees Retirement System now owns 188,900 shares of the company’s stock valued at $3,980,000 after buying an additional 500 shares during the period. Hantz Financial Services Inc. lifted its position in shares of Avantor by 2.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 24,900 shares of the company’s stock worth $644,000 after purchasing an additional 503 shares during the last quarter. Blue Trust Inc. lifted its position in shares of Avantor by 6.9% during the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company’s stock worth $170,000 after purchasing an additional 522 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Avantor by 0.5% during the 4th quarter. Pacer Advisors Inc. now owns 99,825 shares of the company’s stock worth $2,103,000 after purchasing an additional 542 shares during the last quarter. Finally, Veracity Capital LLC lifted its position in shares of Avantor by 1.0% during the 3rd quarter. Veracity Capital LLC now owns 52,359 shares of the company’s stock worth $1,355,000 after purchasing an additional 543 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.